Lenalidomid Puren

Lenalidomide, the active ingredient in Lenalidomid Puren, is a immunomodulatory drug (IMiD) presented as a strength/form for oral use. It treats multiple myeloma, mantle cell lymphoma and myelodysplastic syndromes in adult patients.

GNH USA supplies Lenalidomid Puren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is used in hematologic malignancies that respond to immunomodulatory therapy. - Multiple myeloma: improves progression‑free survival and overall response rates in relapsed or refractory disease. - Mantle cell lymphoma: contributes to disease control in patients who have received prior therapies. - Myelodysplastic syndromes: reduces transfusion dependence and may improve blood counts in patients with del(5q) cytogenetic abnormality.

Common adverse reactions observed with lenalidomide include hematologic and gastrointestinal events.

Common Side Effects: - Neutropenia: decreased neutrophil count increasing infection risk. - Thrombocytopenia: reduced platelet count leading to bleeding tendency. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require supportive care.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism requiring immediate medical attention. - Secondary primary malignancies: emergence of new cancers distinct from the original disease. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Patients should be monitored closely for hematologic and thrombotic complications. - Baseline blood counts: obtain complete blood count before initiating therapy. - Anticoagulation assessment: evaluate need for prophylactic anticoagulation in high‑risk patients. - Pregnancy avoidance: ensure effective contraception for both male and female patients of reproductive potential. - Renal function monitoring: adjust therapy based on creatinine clearance. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lenalidomide may interact with drugs that affect its metabolism or increase thrombotic risk.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure. - Anticoagulants (warfarin, DOACs): additive risk of bleeding.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., cyclosporine): may increase infection susceptibility. - Vaccines: live attenuated vaccines should be avoided during treatment. - NSAIDs: concurrent use may exacerbate thrombocytopenia.